Innoviva, Inc. (INVA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US45781M1018
Innoviva, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 411.33 m USD |
| Gross profit | 307.67 m USD |
| Operating income | 163.75 m USD |
| EBIT | 343.56 m USD |
| Net income | 271.17 m USD |
| Diluted EPS – continuing operations | 3.30 USD |
Full history since 2000, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Innoviva, Inc.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
More stocks
- INNODATA INC (INOD)
- Carabao Group Public Company Limited (CBG.BK)
- Haian Rubber Grp Co Ltd (001233.SZ)
- Hemlo Mining Corp (HMMC.V)
- Cardinal Energy Ltd (Alberta) (CJ.TO)
- Fraser and Neave Ltd (F99.SI)
- Bittium Oyj (BITTI.HE)
- SAFETY INSURANCE GROUP INC (SAFT)
- NATURAL RESOURCE PARTNERS LP (NRP)
- OCULAR THERAPEUTIX, INC (OCUL)
- Sesa SpA (SES.MI)
- Chongqing Iron & Steel Co Ltd Class A (601005.SS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.